Can-Fite BioPharma looks forward to completing enrollment of its Phase IIl study to treat psoriasis

Retrieved on: 2021-06-01 16:41:15

Tags for this article:

Click the tags to see associated articles and topics

Can-Fite BioPharma looks forward to completing enrollment of its Phase IIl study to treat psoriasis. View article details on hiswai:

Excerpt

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) (TASE:CFBI) CEO Pnina Fishman tells Proactive the Petach Tikva, Israel-based biotechnology ...

Article found on: www.proactiveinvestors.com